BANZEL (rufinamide) tablets are indicated as adjunctive (add-on) therapy in the treatment of seizures associated with Lennox-Gastaut syndrome (see above) in children 4 years and older and in adults. Usually, Banzel is added when another seizure medicine is not controlling all seizures, rather than being used by itself; however, an experienced physician may choose to try Banzel as a single agent in some circumstances (so-called off-label use).

A variety of seizure types may respond to Banzel, including partial and generalized seizures. In the clinical trials an improvement in seizures was much more likely than was complete elimination of seizures, and not all patients had even an improvement.